NWBO (Northwest Biotherapeutics) Debt-to-Asset : 1.99 (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Debt-to-Asset?

Northwest Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $29.04 Mil. Northwest Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $29.30 Mil. Northwest Biotherapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $29.32 Mil. Northwest Biotherapeutics's debt to asset for the quarter that ended in Sep. 2024 was 1.99.

Northwest Biotherapeutics Debt-to-Asset Historical Data

The historical data trend for Northwest Biotherapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Debt-to-Asset Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

1.69

0.60

0.95

0.84

1.64

Northwest Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															1.19	1.64	1.72	1.97	1.99

Competitive Comparison of Northwest Biotherapeutics's Debt-to-Asset

For the Biotechnology subindustry, Northwest Biotherapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Debt-to-Asset falls into.

Northwest Biotherapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Northwest Biotherapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.794	+	24.766)	/	27.865
	=	1.64

Northwest Biotherapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(29.038	+	29.297)	/	29.321
	=	1.99

Northwest Biotherapeutics (OTCPK:NWBO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Northwest Biotherapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Executives

Navid Malik	director	1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch	officer: Chief Technical Officer	22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton	director, officer: Chief Scientific Officer	22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman	officer: See Remarks	C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers	director, 10 percent owner, officer: President and CEO	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski	director	C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis	officer: See Remarks	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer	director	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp	10 percent owner	27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund	10 percent owner	C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc.	10 percent owner	7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer	director	10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr.	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814